Loading the company…
Loading the company…
In the last ten years FDA made 2 decisions for Nuvascular (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (1). The latest was on 2026-06-12.
| Family | Decisions on record |
|---|---|
| Tumor & fibroid embolization | 2 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-06-12 | 510(k) | K260635 | HARBOR Occlusion Device |
| 2025-07-09 | 510(k) | K250133 | HARBOR Occlusion Device |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Nuvascular.
In 2025, Nuvascular reported engagement with 2 surgeons and other clinicians in the states MedaRep covers, worth $16K in consulting, speaking, meals and travel for its device products, the most in New York ($14K to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($14K, 1 engaged), Tennessee ($2,400, 1 engaged).